Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia
Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients re...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2023-04, Vol.117 (4), p.530-537 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 537 |
|---|---|
| container_issue | 4 |
| container_start_page | 530 |
| container_title | International journal of hematology |
| container_volume | 117 |
| creator | Zhang, Xian Wu, Shulan Yang, Junfang Zhang, Gailing Su, Yunchao Zhang, Min He, Jiujiang Shi, Yanze Li, Wenqian Lu, Peihua Lu, Daopei |
| description | Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of chemotherapy followed by AS4S4 maintenance for 3 years. Eighty-eight ND APL patients were treated with either oral AS4S4 (
n
= 42) or arsenic trioxide (ATO) (
n
= 46). The 8-year overall survival (OS) rate was 100% in the AS4S4 group and 90% in the ATO group. The disease-free survival (DFS) rates were 100% and 87.1% (
p
= 0.027), respectively. Patients in the ATO group had more side effects. A subsequent cohort of 33 ND APL patients received triple therapy with oral AS4S4, ATRA, and chemotherapy. The 13-year OS and DFS rates were 100% and 90.9%. Our long-term analyses show that APL patients with oral AS4S4 had better outcomes compared to ATO, with no need for hospitalization. |
| doi_str_mv | 10.1007/s12185-022-03507-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2759266348</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890340006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-84099042c01d42497a0d48698a9b928a5c9755a01fbbe4c63c33443ac564ad83</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EotPCH2CBLLFhE7h-xfESVTwqjcSme8txbjouSTzYTlH-PR6mgMSClaV7vnN8dQ8hrxi8YwD6fWacdaoBzhsQCnSjnpAd61rVCK3lU7IDw1WjNIMLcpnzPQDTIPVzciFa1VWb3pGHfVzumoJppglLivmIvoQHpLmsw0bjeBqHJQZPnQ8D9XHuw4ID_RHKgbqUcTlJS1UOOMdywOSOGx1jqvxakB5TnDecot9KBSdcv-Ec3AvybHRTxpeP7xW5_fTx9vpLs__6-eb6w77xwpjSdBKMAck9sEFyabSDQXat6ZzpDe-c8kYr5YCNfY_St8ILIaVwXrXSDZ24Im_PsXWL7yvmYueQPU6TWzCu2XKtDG9bIU_om3_Q-7impS5neWdASABoK8XPlK-nyglHe0xhdmmzDOypFHsuxdbr2l-lWFVNrx-j137G4Y_ldwsVEGcgV2m5w_T37__E_gS_ZphN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890340006</pqid></control><display><type>article</type><title>Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zhang, Xian ; Wu, Shulan ; Yang, Junfang ; Zhang, Gailing ; Su, Yunchao ; Zhang, Min ; He, Jiujiang ; Shi, Yanze ; Li, Wenqian ; Lu, Peihua ; Lu, Daopei</creator><creatorcontrib>Zhang, Xian ; Wu, Shulan ; Yang, Junfang ; Zhang, Gailing ; Su, Yunchao ; Zhang, Min ; He, Jiujiang ; Shi, Yanze ; Li, Wenqian ; Lu, Peihua ; Lu, Daopei</creatorcontrib><description>Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of chemotherapy followed by AS4S4 maintenance for 3 years. Eighty-eight ND APL patients were treated with either oral AS4S4 (
n
= 42) or arsenic trioxide (ATO) (
n
= 46). The 8-year overall survival (OS) rate was 100% in the AS4S4 group and 90% in the ATO group. The disease-free survival (DFS) rates were 100% and 87.1% (
p
= 0.027), respectively. Patients in the ATO group had more side effects. A subsequent cohort of 33 ND APL patients received triple therapy with oral AS4S4, ATRA, and chemotherapy. The 13-year OS and DFS rates were 100% and 90.9%. Our long-term analyses show that APL patients with oral AS4S4 had better outcomes compared to ATO, with no need for hospitalization.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-022-03507-5</identifier><identifier>PMID: 36580227</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Acute promyeloid leukemia ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Arsenic ; Arsenic - therapeutic use ; Arsenic trioxide ; Arsenic Trioxide - therapeutic use ; Arsenicals - adverse effects ; Chemotherapy ; Hematology ; Humans ; Leukemia ; Leukemia, Promyelocytic, Acute - therapy ; Medicine ; Medicine & Public Health ; Mitoxantrone ; Oncology ; Original Article ; Oxides - adverse effects ; Promyeloid leukemia ; Remission ; Retinoic acid ; Retrospective Studies ; Side effects ; Survival ; Treatment Outcome ; Tretinoin - therapeutic use</subject><ispartof>International journal of hematology, 2023-04, Vol.117 (4), p.530-537</ispartof><rights>Japanese Society of Hematology 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. Japanese Society of Hematology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-84099042c01d42497a0d48698a9b928a5c9755a01fbbe4c63c33443ac564ad83</citedby><cites>FETCH-LOGICAL-c399t-84099042c01d42497a0d48698a9b928a5c9755a01fbbe4c63c33443ac564ad83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-022-03507-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-022-03507-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36580227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xian</creatorcontrib><creatorcontrib>Wu, Shulan</creatorcontrib><creatorcontrib>Yang, Junfang</creatorcontrib><creatorcontrib>Zhang, Gailing</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Zhang, Min</creatorcontrib><creatorcontrib>He, Jiujiang</creatorcontrib><creatorcontrib>Shi, Yanze</creatorcontrib><creatorcontrib>Li, Wenqian</creatorcontrib><creatorcontrib>Lu, Peihua</creatorcontrib><creatorcontrib>Lu, Daopei</creatorcontrib><title>Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of chemotherapy followed by AS4S4 maintenance for 3 years. Eighty-eight ND APL patients were treated with either oral AS4S4 (
n
= 42) or arsenic trioxide (ATO) (
n
= 46). The 8-year overall survival (OS) rate was 100% in the AS4S4 group and 90% in the ATO group. The disease-free survival (DFS) rates were 100% and 87.1% (
p
= 0.027), respectively. Patients in the ATO group had more side effects. A subsequent cohort of 33 ND APL patients received triple therapy with oral AS4S4, ATRA, and chemotherapy. The 13-year OS and DFS rates were 100% and 90.9%. Our long-term analyses show that APL patients with oral AS4S4 had better outcomes compared to ATO, with no need for hospitalization.</description><subject>Acute promyeloid leukemia</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Arsenic</subject><subject>Arsenic - therapeutic use</subject><subject>Arsenic trioxide</subject><subject>Arsenic Trioxide - therapeutic use</subject><subject>Arsenicals - adverse effects</subject><subject>Chemotherapy</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Promyelocytic, Acute - therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mitoxantrone</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Oxides - adverse effects</subject><subject>Promyeloid leukemia</subject><subject>Remission</subject><subject>Retinoic acid</subject><subject>Retrospective Studies</subject><subject>Side effects</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Tretinoin - therapeutic use</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtv1DAUhS0EotPCH2CBLLFhE7h-xfESVTwqjcSme8txbjouSTzYTlH-PR6mgMSClaV7vnN8dQ8hrxi8YwD6fWacdaoBzhsQCnSjnpAd61rVCK3lU7IDw1WjNIMLcpnzPQDTIPVzciFa1VWb3pGHfVzumoJppglLivmIvoQHpLmsw0bjeBqHJQZPnQ8D9XHuw4ID_RHKgbqUcTlJS1UOOMdywOSOGx1jqvxakB5TnDecot9KBSdcv-Ec3AvybHRTxpeP7xW5_fTx9vpLs__6-eb6w77xwpjSdBKMAck9sEFyabSDQXat6ZzpDe-c8kYr5YCNfY_St8ILIaVwXrXSDZ24Im_PsXWL7yvmYueQPU6TWzCu2XKtDG9bIU_om3_Q-7impS5neWdASABoK8XPlK-nyglHe0xhdmmzDOypFHsuxdbr2l-lWFVNrx-j137G4Y_ldwsVEGcgV2m5w_T37__E_gS_ZphN</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Zhang, Xian</creator><creator>Wu, Shulan</creator><creator>Yang, Junfang</creator><creator>Zhang, Gailing</creator><creator>Su, Yunchao</creator><creator>Zhang, Min</creator><creator>He, Jiujiang</creator><creator>Shi, Yanze</creator><creator>Li, Wenqian</creator><creator>Lu, Peihua</creator><creator>Lu, Daopei</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20230401</creationdate><title>Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia</title><author>Zhang, Xian ; Wu, Shulan ; Yang, Junfang ; Zhang, Gailing ; Su, Yunchao ; Zhang, Min ; He, Jiujiang ; Shi, Yanze ; Li, Wenqian ; Lu, Peihua ; Lu, Daopei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-84099042c01d42497a0d48698a9b928a5c9755a01fbbe4c63c33443ac564ad83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute promyeloid leukemia</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Arsenic</topic><topic>Arsenic - therapeutic use</topic><topic>Arsenic trioxide</topic><topic>Arsenic Trioxide - therapeutic use</topic><topic>Arsenicals - adverse effects</topic><topic>Chemotherapy</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Promyelocytic, Acute - therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mitoxantrone</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Oxides - adverse effects</topic><topic>Promyeloid leukemia</topic><topic>Remission</topic><topic>Retinoic acid</topic><topic>Retrospective Studies</topic><topic>Side effects</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Tretinoin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xian</creatorcontrib><creatorcontrib>Wu, Shulan</creatorcontrib><creatorcontrib>Yang, Junfang</creatorcontrib><creatorcontrib>Zhang, Gailing</creatorcontrib><creatorcontrib>Su, Yunchao</creatorcontrib><creatorcontrib>Zhang, Min</creatorcontrib><creatorcontrib>He, Jiujiang</creatorcontrib><creatorcontrib>Shi, Yanze</creatorcontrib><creatorcontrib>Li, Wenqian</creatorcontrib><creatorcontrib>Lu, Peihua</creatorcontrib><creatorcontrib>Lu, Daopei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xian</au><au>Wu, Shulan</au><au>Yang, Junfang</au><au>Zhang, Gailing</au><au>Su, Yunchao</au><au>Zhang, Min</au><au>He, Jiujiang</au><au>Shi, Yanze</au><au>Li, Wenqian</au><au>Lu, Peihua</au><au>Lu, Daopei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>117</volume><issue>4</issue><spage>530</spage><epage>537</epage><pages>530-537</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of chemotherapy followed by AS4S4 maintenance for 3 years. Eighty-eight ND APL patients were treated with either oral AS4S4 (
n
= 42) or arsenic trioxide (ATO) (
n
= 46). The 8-year overall survival (OS) rate was 100% in the AS4S4 group and 90% in the ATO group. The disease-free survival (DFS) rates were 100% and 87.1% (
p
= 0.027), respectively. Patients in the ATO group had more side effects. A subsequent cohort of 33 ND APL patients received triple therapy with oral AS4S4, ATRA, and chemotherapy. The 13-year OS and DFS rates were 100% and 90.9%. Our long-term analyses show that APL patients with oral AS4S4 had better outcomes compared to ATO, with no need for hospitalization.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>36580227</pmid><doi>10.1007/s12185-022-03507-5</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2023-04, Vol.117 (4), p.530-537 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2759266348 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acute promyeloid leukemia Antineoplastic Combined Chemotherapy Protocols - adverse effects Arsenic Arsenic - therapeutic use Arsenic trioxide Arsenic Trioxide - therapeutic use Arsenicals - adverse effects Chemotherapy Hematology Humans Leukemia Leukemia, Promyelocytic, Acute - therapy Medicine Medicine & Public Health Mitoxantrone Oncology Original Article Oxides - adverse effects Promyeloid leukemia Remission Retinoic acid Retrospective Studies Side effects Survival Treatment Outcome Tretinoin - therapeutic use |
| title | Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A46%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20retrospective%20study%20of%20retinoic%20acid%20combined%20with%20arsenic%20and%20chemotherapy%20for%20acute%20promyelocytic%20leukemia&rft.jtitle=International%20journal%20of%20hematology&rft.au=Zhang,%20Xian&rft.date=2023-04-01&rft.volume=117&rft.issue=4&rft.spage=530&rft.epage=537&rft.pages=530-537&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-022-03507-5&rft_dat=%3Cproquest_cross%3E2890340006%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890340006&rft_id=info:pmid/36580227&rfr_iscdi=true |